• br Conflict of interest br

  2023-09-14

  

  Conflict of interest Acknowledgments This work was supported by research grant [PR26/20326] from Santander Bank/UCM. The authors would like to thank Miguel Capo, Professor of Toxicology from the Universidad Complutense de Madrid, for his counseling during the preparation of the present work.

• AUY922 br In our experience br History of

  2023-09-14

  

  In our experience History of ER and ACh tests As shown in Table 1, Stein et al. first reported the usefulness of intravenous injection of ER in diagnosing coronary insufficiency in 1949 [16]. In 1972, the first ER spasm provocation test was employed at the Cleveland Clinic during cardiac cathe

• br Funding br Introduction The

  2023-09-14

  

  Funding Introduction The interest in the effects of endocrine disrupting chemicals (EDCs) in the aquatic environment continues to increase over the past decade, specifically those that act on steroidogenic pathways. EDCs that include synthetic androgenic and estrogenic compounds can severely a

• In our H K ATPase

  2023-09-14

  

  In our H+, K+-ATPase assay (Fig. 1 and Supplementary Fig. 1), myricetin (IC50 = 0.58μM) was more potent than acid-activated omeprazole (IC50 = 1.50μM). In contrast, in oral administration in mice (Fig. 3), omeprazole (20mg/kg) more effectively inhibited gastric LP533401 hcl mg secretion compared to

• In this study significant reduction in

  2023-09-14

  

  In this study, significant reduction in the HCO3− content in sham-operated and testosterone-treated rats following bafilomycin A1 administration suggested that V-ATPase could be involved in mediating the decrease in vas deferens fluid HCO3− content, most probably due to the increase in H+ secretion

• br Experimental Procedures Additional information can be

  2023-09-14

  

  Experimental Procedures Additional information can be found in Supplemental Experimental Procedures. Author Contributions Acknowledgments We thank all members of Lab of Health Chemistry for helpful discussions. This work was supported by Grant-in-Aid for Scientific Research (KAKENHI) from

• In summary this report demonstrates

  2023-09-14

  

  In summary, this report demonstrates another successful application of gene editing in iPSCs. Despite the lack of efficient metabolic functional repair after transplantation, the application of gene correction into HLCs might still be a realistic goal for ex vivo gene therapy of liver diseases with

• br COPD As in asthma also in

  2023-09-14

  

  COPD As in asthma, also in COPD, increased expression of arginase has been reported, and tobacco smoke may increase expression of arginase in human subjects [46, 47]. Increased ADMA levels have also been reported in COPD, and both the increased expression of arginase and ADMA contribute to remode

• Another major problem leading to implant failures

  2023-09-14

  

  Another major problem leading to implant failures is post-implant infections, majorly due to bacteria adhesion [13,36,37]. A significant decrease in bacterial counts (~65–90%) has been observed in HA and/or CNT-based composites reinforced with 2.5–10 wt% nano Ag [13,38], thus, drawing the conclusion

• The evaluation of serum electrolytes

  2023-09-14

  

  The evaluation of serum electrolytes (e.g.: sodium, potassium, urea, creatinine, and uric acid), liver transaminases, blood counts (e.g. identification of thrombocytopenia, and bilirubin), 24-h urine (in order to monitor proteinuria), and heart rate and lung function of the mother should be performe

• Kim et al found that hydroxydopamine OHDA promoted the

  2023-09-14

  

  Kim et al. (2013) found that 6-hydroxydopamine (6-OHDA) promoted the atrophy of dopaminergic neurons associated with the activation of poly (ADP-ribose) polymerase (PARP), the translocation of apoptosis inductor factor (AIF) and the depletion of ATP. An increase in p-AMPK and pS6K (upstream kinase o

• Perhaps the first evidence of AMPKs therapeutic ability in

  2023-09-14

  

  Perhaps the first evidence of AMPKs therapeutic ability in DM1 came from Thomas Cooper’s laboratory where they demonstrated that insulin-independent glucose uptake was unaffected in human DM1 muscle SKL2001 mg treated with MET, an AMPK activator and first-line therapy for type 2 diabetes mellitus [7

• Kuda et al reported that the activity of

  2023-09-13

  

  Kuda et al. (1997) reported that the activity of aminopeptidase A (ApA) but not aminopeptidase B (ApB) nor aminopeptidase N (ApN) was decreased in plasma from patients with Alzheimer's disease (AD). More recently Puertas et al. (2013) reported that the activities of plasma ApA, ApB, ApN and IRAP wer

• APPL was the first adaptor protein identified that interacts

  2023-09-13

  

  APPL1 was the first adaptor protein identified that interacts directly with adiponectin receptors [18]. A two-hybrid study by Dong and colleagues revealed that the C-terminal extracellular domain of AdipoR1 interacts with adiponectin, whereas the N-terminal cytoplasmic domain of AdipoR1 interacts wi

• Pituitary adenylate cyclase activating polypeptide PACAP

  2023-09-13

  

  Pituitary adenylate cyclase-activating polypeptide (PACAP) is a member of the secretin/growth hormone-releasing hormone (GHRH)/vasoactive intestinal peptide (VIP) family, with potent anti-inflammatory and potent cytoprotective properties [[6], [7], [8], [9], [10], [11], [12], [13]]. PACAP exists as

14860 records 231/991 page Previous Next First page 上5页 231232233234235 下5页 Last page